Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leor Roseman

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Journal of Psychopharmacology (Oxford, England)|December 26, 2024
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapyLeor Roseman
Neuropharmacology|November 5, 2022
More than meets the eye: The role of sensory dimensions in psychedelic brain dynamics, experience, and therapeuticsMarco Aqil, Leor Roseman
Frontiers in Psychology|September 13, 2021
On Revelations and Revolutions: Drinking Ayahuasca Among Palestinians Under Israeli OccupationLeor Roseman, Nadeem Karkabi
Frontiers in Psychiatry|May 14, 2023
Psychedelic-induced mystical experiences: An interdisciplinary discussion and critiqueSharday Mosurinjohn, Leor Roseman, Manesh Girn
Discover Mental Health|March 21, 2026
Towards social curative psychedelic treatmentMartha Newson, Leor Roseman, S Alexander Haslam
Nature Medicine|June 3, 2025
An international Delphi consensus for reporting of setting in psychedelic clinical trialsChloé Pronovost-Morgan, Kyle T Greenway, Leor Roseman, et al.
Frontiers in Pharmacology|February 2, 2018
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant DepressionLeor Roseman, David J Nutt, Robin L Carhart-Harris
Frontiers in Pharmacology|August 8, 2022
Editorial: Psychedelic sociality: Pharmacological and extrapharmacological perspectivesLeor Roseman, Katrin H Preller, Evgenia Fotiou, et al.
JAMA Network Open|July 15, 2024
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience EfficacyLeor Roseman, David Erritzoe, David Nutt, et al.
The American Journal of Psychiatry|January 1, 2024
Is Poorly Assisted Psilocybin Treatment an Increasing Risk?Eduardo Ekman Schenberg, Franklin King, João Eusébio da Fonseca, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Journal of Psychopharmacology (Oxford, England)|December 26, 2024
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapyLeor Roseman
Neuropharmacology|November 5, 2022
More than meets the eye: The role of sensory dimensions in psychedelic brain dynamics, experience, and therapeuticsMarco Aqil, Leor Roseman
Frontiers in Psychology|September 13, 2021
On Revelations and Revolutions: Drinking Ayahuasca Among Palestinians Under Israeli OccupationLeor Roseman, Nadeem Karkabi
Frontiers in Psychiatry|May 14, 2023
Psychedelic-induced mystical experiences: An interdisciplinary discussion and critiqueSharday Mosurinjohn, Leor Roseman, Manesh Girn
Discover Mental Health|March 21, 2026
Towards social curative psychedelic treatmentMartha Newson, Leor Roseman, S Alexander Haslam
Nature Medicine|June 3, 2025
An international Delphi consensus for reporting of setting in psychedelic clinical trialsChloé Pronovost-Morgan, Kyle T Greenway, Leor Roseman, et al.
Frontiers in Pharmacology|February 2, 2018
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant DepressionLeor Roseman, David J Nutt, Robin L Carhart-Harris
Frontiers in Pharmacology|August 8, 2022
Editorial: Psychedelic sociality: Pharmacological and extrapharmacological perspectivesLeor Roseman, Katrin H Preller, Evgenia Fotiou, et al.
JAMA Network Open|July 15, 2024
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience EfficacyLeor Roseman, David Erritzoe, David Nutt, et al.
The American Journal of Psychiatry|January 1, 2024
Is Poorly Assisted Psilocybin Treatment an Increasing Risk?Eduardo Ekman Schenberg, Franklin King, João Eusébio da Fonseca, et al.
Pageof 9